Transcutaneous auricular neurostimulation for neonatal abstinence syndrome
Transcutaneous auricular neurostimulation for neonatal abstinence syndrome
批准号:
9910282
负责人:
DOROTHEA DENISE JENKINS
金额:
$21.77万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-09-30 至 2021-02-28
关键词:
AcademyAccountingAcupuncture TherapyAdultAdverse eventAmendmentAmericanBirthBradycardiaBreast FeedingBurn injuryCaloriesClinicalClonidineConvulsionsCryingDeglutitionDevicesEarEar AcupunctureEnvironmentEquipmentExhibitsExposure toFecesGoldHealth ExpendituresHearing AidsHeart RateHeroinHourHydrogelsInfantInstitutional Review BoardsInterventionLasersLengthLength of StayMeasuresMedicalMedical DeviceMedicineMethadoneMonitorMorphineMuscle TonusNeedlesNeonatalNeonatal Abstinence SyndromeNeonatal Intensive Care UnitsNerveNeural PathwaysNeuraxisNewborn InfantOpioidOralPainPatientsPediatricsPharmaceutical PreparationsPharmacotherapyPhenobarbitalProtocols documentationRespiratory Signs and SymptomsRiskSensory ThresholdsSouth CarolinaStressSymptomsTechniquesTechnologyTherapeuticTreatment CostTreatment ProtocolsTremorTrigeminal SystemUniversitiesVomitingWithdrawalWithdrawal Symptombaseexperiencefeedinggastrointestinalgastrointestinal symptomimprovedin uteromorphine administrationmultimodalityneonatenutritionopen labelopioid withdrawalprospectiverecruitrespiratorysafety and feasibilitysedativeside effectskin irritationstandard of caresuckingtreatment durationvagus nerve stimulation
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Neonatal abstinence syndrome (NAS) is a condition in which infants undergo withdrawal after exposure to
prescription or non-prescription opioids such as methadone or heroin in utero. NAS babies exhibit hyperirritability
of the central nervous system and respiratory, gastrointestinal, and autonomic symptoms. These symptoms
usually appear within 48 to 72 hours after birth. As of 2012, an infant with NAS was born every 25 minutes in the
US, accounting for more than $1.5 billion in national healthcare expenditures. Between 2000–2012, national
rates of NAS increased 383% from 1.2 per 1000 births to 5.8 per 1000 births. These infants frequently require
hospital stay in a neonatal intensive care unit (NICU) with an average hospital stay of 25 days at an average
treatment cost of $66K.
Currently, no nationwide standard of care exists for managing NAS. Treatment of NAS usually follows a
multimodal regime based on drug therapy with an oral morphine solution, mostly in combination with a sedative.
This approach is clearly controversial as it can impart additional stress on the newborn, thus the need for a
sedative. The American Academy of Pediatrics recommends attempting the use of non-pharmacologic
treatment, which includes placing the infant in a dark and quiet environment, swaddling, rocking, breastfeeding,
and providing high-calorie nutrition in frequent small feedings, among other techniques. When utilized
appropriately, such non-pharmacological interventions have resulted in a reduction in length of stay, length of
treatment, and percentage of infants requiring pharmacotherapy.
Auricular acupuncture has recently been studids as an adjunctive therapy for NAS newborns. The use of non-
insertive acupuncture (NIA) using traditional needles or a handheld laser has resulted in some of NAS babies
becoming more relaxed during their course of treatment. While more indepth studies are needed to evaluate NIA
as an effective adjunct therapy for NAS newborns, the early results show promise of tapping into the auricular
neural pathways for treating NAS.
While acupuncture is quite safe and requires no specialized equipment, the results of the technique can vary
widely depending on who is applying the therapy. We propose to develop a transcutaneous auricular
neurostimulation device to help NAS babies recover from opioid withdrawal without harmful side effects. The
non-invasive, auricular neurostimulation device will be placed around the ear (similar to a hearing aid) and
stimulation will be delivered transcutaneously.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
BabyStrong taVNS-Paired BottleFeeding to Improve Oral Feeding
-
批准号:10258359
-
项目类别:
-
资助金额:$31.87万
-
财政年份:2021
-
负责人:DOROTHEA DENISE JENKINS
-
依托单位:
Delivering Transcutaneous Auricular Neurostimulation as an Adjunct Treatment for Neonatal Opioid Withdrawal Syndrome
-
批准号:10390149
-
项目类别:
-
资助金额:$124.97万
-
财政年份:2019
-
负责人:DOROTHEA DENISE JENKINS
-
依托单位:
Delivering Transcutaneous Auricular Neurostimulation as an Adjunct Treatment for Neonatal Opioid Withdrawal Syndrome
-
批准号:10491343
-
项目类别:
-
资助金额:$124.8万
-
财政年份:2019
-
负责人:DOROTHEA DENISE JENKINS
-
依托单位:
Safety of N-acetylcysteine in Maternal Chorioamnionitis
-
批准号:7204317
-
项目类别:
-
资助金额:$54.62万
-
财政年份:2007
-
负责人:DOROTHEA DENISE JENKINS
-
依托单位:
Safety of N-acetylcysteine in Maternal Chorioamnionitis
-
批准号:7365160
-
项目类别:
-
资助金额:$54.99万
-
财政年份:2007
-
负责人:DOROTHEA DENISE JENKINS
-
依托单位:
Safety of N-acetylcysteine in Maternal Chorioamnionitis
-
批准号:7575081
-
项目类别:
-
资助金额:$44.16万
-
财政年份:2007
-
负责人:DOROTHEA DENISE JENKINS
-
依托单位:
NEONATAL ENCEPHALOPATHY TREATED BY MODERATE HYPOTHERMIA
-
批准号:6149383
-
项目类别:
-
资助金额:$3.0万
-
财政年份:1999
-
负责人:DOROTHEA DENISE JENKINS
-
依托单位:
NEONATAL ENCEPHALOPATHY TREATED BY MODERATE HYPOTHERMIA
-
批准号:6394031
-
项目类别:
-
资助金额:$24.54万
-
财政年份:1999
-
负责人:DOROTHEA DENISE JENKINS
-
依托单位:
NEONATAL ENCEPHALOPATHY TREATED BY MODERATE HYPOTHERMIA
-
批准号:2903321
-
项目类别:
-
资助金额:$25.61万
-
财政年份:1999
-
负责人:DOROTHEA DENISE JENKINS
-
依托单位:
NEONATAL ENCEPHALOPATHY TREATED BY MODERATE HYPOTHERMIA
-
批准号:6188181
-
项目类别:
-
资助金额:$23.32万
-
财政年份:1999
-
负责人:DOROTHEA DENISE JENKINS
-
依托单位:
海外基金